Wall Street analysts forecast that Bellerophon Therapeutics Inc (NASDAQ:BLPH) will post earnings of ($0.12) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics posted earnings of ($0.22) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 45.5%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 6th.
On average, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($0.40) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will post earnings of ($0.54) per share. Zacks’ EPS averages are an average based on a survey of analysts that that provide coverage for Bellerophon Therapeutics.
Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.10).
A number of research firms have recently issued reports on BLPH. Zacks Investment Research lowered shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 11th. ValuEngine upgraded shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Bellerophon Therapeutics in a research note on Thursday, August 2nd.
Shares of BLPH traded up $0.01 during mid-day trading on Friday, reaching $1.16. 4,027 shares of the stock traded hands, compared to its average volume of 1,168,604. The firm has a market capitalization of $64.73 million, a P/E ratio of -1.29 and a beta of -0.84. Bellerophon Therapeutics has a 12-month low of $0.47 and a 12-month high of $3.30.
In other news, major shareholder Associates Iv L. P. Venrock purchased 50,000 shares of Bellerophon Therapeutics stock in a transaction dated Wednesday, September 5th. The stock was bought at an average price of $0.85 per share, with a total value of $42,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Associates Iv L. P. Venrock purchased 529,370 shares of Bellerophon Therapeutics stock in a transaction dated Thursday, August 16th. The shares were purchased at an average cost of $0.65 per share, with a total value of $344,090.50. The disclosure for this purchase can be found here. In the last three months, insiders have bought 1,699,370 shares of company stock valued at $1,672,941. Corporate insiders own 57.80% of the company’s stock.
An institutional investor recently bought a new position in Bellerophon Therapeutics stock. DRW Securities LLC acquired a new position in Bellerophon Therapeutics Inc (NASDAQ:BLPH) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 70,000 shares of the biotechnology company’s stock, valued at approximately $146,000. DRW Securities LLC owned 0.12% of Bellerophon Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 58.49% of the company’s stock.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
Recommended Story: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.